

25 Summary of main points: Two potential factors, timing of vaccination and clinical infection history,
26 cannot fully explain the increased influenza infection risk in repeat vaccinees compared with non-
27 repeat vaccinees. Subclinical infection in the previous season may explain the effect.

28 1 Abstract¹

29 Studies have reported that prior-season influenza vaccination is associated with higher risk of clinical
30 influenza infection among vaccinees. This effect might arise from incomplete consideration of within-
31 season waning and recent infection. Using data from the US Flu Vaccine Effectiveness (VE) Network
32 (2011-2012 to 2018-2019 seasons), we found that repeat vaccinees were vaccinated earlier in a
33 season by one week. After accounting for waning VE, repeat vaccinees were still more likely to test
34 positive for A(H3N2) (OR=1.11, 95%CI:1.02-1.21) but not for influenza B or A(H1N1). We found that
35 clinical infection influenced individuals' decision to vaccinate in the following season while protecting
36 against clinical infection of the same (sub)type. However, adjusting for recent clinical infections did
37 not strongly influence the estimated effect of prior-season vaccination. In contrast, we found that
38 adjusting for subclinical infection could theoretically attenuate this effect. Additional investigation is
39 needed to determine the impact of subclinical infections on VE.

40 Key words: influenza; vaccine; waning vaccine protection; infection history; infection block
41 hypothesis; immunogenicity; test negative design

42 2 Introduction

43

44 The World Health Organization recommends annual influenza vaccination of persons at high risk,
45 with some countries recommending universal vaccination[1,2]. A controlled study in the 1970s first

¹ The authors report no conflict of interest; This study was partially supported by the Collaborative Influenza Vaccine Innovation Centers (CIVICs) contract 75N93019C00051 (S.C. and Q.B.). ML acknowledges support from US NIH grant 1R01GM139926 to University of Michigan. Corresponding author's contact information: Qifang.bi@gmail.com. Alternative corresponding author: Sarah Cobey. Contact information of the alternative corresponding author: cobey@uchicago.edu. Data and relevant code are available at https://github.com/cobeylab/FluVE_repeatvac_public. The analyses were conducted in R version 4.1.1.

46 raised questions about repeated annual influenza vaccination, reporting that prior vaccination
47 indirectly increased the risk of infection in the current season[3,4]. It was not until a test-negative
48 study in Canada[5], a vaccine trial in Hong Kong[6] and a household-based study in the United
49 States[7] found differences in vaccine effectiveness (VE) and immunogenicity among repeat
50 vaccinees and non-repeat vaccinees in the 2009/10 and 2010/11 seasons that the phenomenon was
51 investigated routinely[8–14]. Since then, increased infection risk against A(H3N2) in repeat vaccinees
52 was observed in multiple seasons and countries[7,11,12,13,15,16]. Increased risk is less often
53 reported for the less prevalent A(H1N1) and type B[8,9].

54 Test-negative studies conducted in healthcare settings have become the standard way to evaluate
55 vaccine protection. A test-negative design estimates VE by comparing vaccination coverage in
56 persons with a medically attended acute respiratory illness who test positive for influenza with those
57 who test negative[17]. Several factors that may bias estimates of repeat vaccination effects in test-
58 negative design have not been considered.

59 Vaccine-induced protection against influenza virus infection wanes within a season[18–22].
60 Consequently, the vaccine protection estimated among otherwise similar vaccinees may differ if the
61 timing of vaccination is not considered. If repeat vaccinees tend to vaccinate substantially earlier in a
62 season, waning protection could make the risk of infection among repeat vaccinees appear higher
63 than in non-repeat vaccinees. The rapidly changing risk of influenza incidence in a season may
64 amplify the difference[23].

65 The infection block hypothesis[4,24–26] suggests that prior vaccinations can block opportunities to
66 experience immunogenic influenza virus infections, which can lead to more cross-reactive and
67 durable immune responses than vaccination[27], especially when circulating viruses differ from
68 vaccine strains[28,29]. If true, the infection-block hypothesis could explain increased risk of infection
69 among repeat vaccinees compared to non-repeat vaccinees: Prior-season vaccination could protect
70 repeat vaccinees against prior-season infection, leaving them less immune protection at the start of
71 an influenza season and hence a higher incidence of clinical infection in that season than non-repeat
72 vaccinees. The difference in risk between the two groups can be further amplified if recent infection

73 improves vaccine immunogenicity and vaccine-induced protection[28], as has also been recently
74 observed for SARS-CoV-2[30].

75 In epidemiologic terms[31], under the infection block hypothesis, infection in the previous season is a
76 mediator between vaccination in the previous season and a clinical infection outcome in the current
77 season. When we estimate the effect of repeated vaccination, infection in the previous season, acting
78 as a mediator, does not inherently introduce bias. However, if infection in the previous season
79 influences the decision to vaccinate in the current season as well as the probability of clinical infection
80 in the current season, then it is also a confounder that can bias the estimated effect of repeated
81 vaccination on clinical infection. Because infection in the previous season may be both a mediator
82 and a confounder, appropriately adjusting for it requires an approach that can handle this treatment-
83 confounder feedback, such as inverse-probability weighting[32].

84 In this study, we first assessed the effect of repeated vaccination after accounting for intra-season
85 waning of vaccine protection (results in Section 4.1). We then assessed whether *clinical* infection in
86 the prior season, a potential confounder, may have biased our estimate of the effect of repeated
87 vaccination (Section 4.2). Finally, we theoretically assessed the plausibility of the infection block
88 hypothesis and enhanced VE from recent *subclinical* infections as explanations for the repeat
89 vaccination effect (Section 4.3).

90 3 Methods

91 3.1 Study setting and population

92

93 During the study period, the US Flu VE Network consisted of five study sites in Wisconsin, Michigan,
94 Washington, Pennsylvania, and Texas[7,10,33,34,35] (Supplemental Section 1). The study used a
95 test-negative design, estimating the odds of influenza infection in individuals who were vaccinated vs
96 unvaccinated. During each enrollment season, outpatients 6 months of age and older were eligible
97 for recruitment if they presented with acute respiratory illness with symptom onset within the last 7 or
98 10 days, depending on the Flu VE site. Each eligible patient completed an enrollment interview that
99 included questions on status of influenza vaccination in the study enrollment season (the current

100 season), influenza vaccination in the immediately preceding season (the previous season),
101 demographic information, and underlying health conditions. Participants were tested for influenza by
102 real-time reverse transcription polymerase chain reaction (rRT-PCR) assay. Influenza-positive
103 samples were first typed and then A-sub- or B-lineage-typed. For simplicity throughout, we refer to
104 individuals with medically attended PCR-confirmed symptomatic influenza virus infection as having
105 “clinical infection”. Influenza vaccination status was confirmed by reviewing immunization records and
106 state registries.

107 We analyzed data collected over 8 seasons (from the 2011-2012 through the 2018-2019 seasons)
108 from all five sites. We excluded individuals who were vaccinated within 14 days of illness onset, for
109 consistency with prior analyses. We excluded individuals who received more than one dose each
110 season before symptom onset and were under 1 year of age at enrollment.

111 To study the impact of clinical infection history, we additionally obtained enrollment history and
112 rRT-PCR testing history from the Marshfield Clinic (MCHS), the US Flu VE Network site in Wisconsin.
113 The study design and the definition of clinical infection were consistent over time. As the primary
114 outpatient and inpatient care provider in its catchment area, MCHS could collect data on enrollment
115 and testing history that are not available from other sites [36]. In particular, participant data are linked
116 across seasons. We analyzed data from the MCHS over 12 seasons (the 2007-2008 through the
117 2018-2019 seasons). The analyses using exclusively MCHS data are described in the subsection
118 ‘Adjustment for clinical infection history’ of Section 3.2, and the results are shown in Section 4.2.

119 3.2 Statistical analyses

120 Accounting for within-season waning of vaccine protection: Using data from the five sites in the US
121 Flu VE Network, we first determined whether the timing of vaccination differed between repeat and
122 non-repeat vaccinees by fitting a linear regression model.

123 Using logistic regression models, we then estimated the relative odds of clinical infection among
124 repeat vaccinees with reference to non-repeat vaccinees after adjusting for time of vaccination in the
125 current season (to account for the waning of vaccine protection; Supplemental Section 3). The study
126 outcome is (sub)type-specific PCR-confirmed clinical infection. Independent variables are an

127 indicator for having been vaccinated 2-9, 10-13, 14-17, 18-21, or over 21 weeks before symptom
128 onset in the current season regardless of prior-season vaccination status (categorization consistent
129 with Ray *et al.*[18]), a dichotomous indicator for having been vaccinated only in the prior season, a
130 dichotomous indicator for having been vaccinated in both the current and the prior season, age
131 group, sex, comorbidity, influenza season, study site, and calendar month of symptom onset.

132 Adjustment for clinical infection history: Because MCHS was the only site that had linked participants'
133 previous study enrollment and infection history, only data from MCHS could be used to assess the
134 impact of clinical infection history.

135 To determine how a clinical infection in the current season is associated with clinical infection with
136 the same and other (sub)types in prior seasons, we assessed the odds ratio of clinical infection in the
137 current season among individuals with no prior clinical infections or clinical infections 3-5 seasons or
138 ≥ 6 seasons ago with reference to those whose last detected clinical infection was 1-2 seasons
139 before the current season (Supplemental Section 4).

140 We then assessed whether clinical infections in the previous season influenced the decision to
141 vaccinate in the current season using logistic regression models. The dependent variable was
142 vaccination in the current season. The model was stratified by previous-season vaccination status,
143 and additionally adjusted for age group, sex, comorbidity, and an indicator of vaccination
144 frequency (Supplemental Section 4).

145 Next, we estimated the effect of repeated vaccination after adjusting for the clinical infection
146 status of any (sub)type in the previous season (Supplemental Section 4). To handle the treatment-
147 confounder feedback, we used inverse-probability weighting to account for clinical infection status of
148 any (sub)type in the previous season, using regression to adjust for baseline covariates. Weights
149 were calculated as the inverse of each individual's probability of being vaccinated in each season
150 given their previous vaccination status, infection status in the prior season, and baseline covariates
151 (i.e., sex, age group, comorbidities, influenza season). These weights were then "stabilized" using the
152 probabilities of being vaccinated given vaccination history, and the above-mentioned baseline
153 covariates (excluding infection status).

154 Impact of subclinical infection: To understand how subclinical infection history, i.e., infections not
155 detected by the US Flu VE Network, may impact the estimated effect of repeated vaccination, we
156 evaluated the proportion of repeat and non-repeat vaccinees who would have had to have been
157 subclinically infected in the previous season to reproduce the estimated effect of repeated
158 vaccination, assuming that the subclinical infection-block hypothesis was the only explanation for the
159 observed elevated risk. We demonstrate that the results are consistent with the hypothesis of
160 enhanced vaccine immunogenicity post-infection.

161 To achieve this objective, we built a theoretical model and created a pseudo-population of repeat and
162 non-repeat vaccinees with various infection statuses in the previous seasons (Supplemental Section
163 5). We derived the relationship between rates of subclinical infections in repeat- and non-repeat
164 vaccinees given various degrees of effectiveness of subclinical infection against future clinical
165 infection (30%, 50%, and 70% reductions in clinical infection risk). We varied assumptions about the
166 protection conferred by clinical and subclinical infection in the prior season against future infection.
167 Based on estimates from prior studies[37,38], we varied clinical attack rates in vaccinated and
168 unvaccinated individuals, assuming either low (1% and 2% for vaccinated and unvaccinated
169 individuals, respectively) or high clinical incidence (3% and 6% respectively).

170 The study obtained the institutional review board approval at participating institutions and the Centers
171 for Disease Control and Prevention.

172 4 Results

173 Between the 2011-2012 and 2018-2019 seasons, individuals enrolled in the US Flu VE Network
174 contributed 61,943 visits, of which 55,728 (90.0%) met the inclusion criteria of our analyses. Of those,
175 50.2% (27,986/55,728) of visits were by individuals who had received one dose of the current
176 seasonal influenza vaccine ≥ 14 days prior to illness onset date (SFig 1.1). Among those vaccinated
177 ≥ 14 days prior to illness onset, 73.7% (20,630/27,986) of visits were by individuals who were
178 vaccinated at least once in the previous season, and whom we refer to as repeat vaccinees (STable
179 1.1).

180

181

182 4.1 Impact of waning vaccine protection

183 On average, repeat vaccinees of similar age, sex, and comorbidities were vaccinated 1.1 (95%CI:1.0-
184 1.2) weeks earlier than non-repeat vaccinees (Figure 1A). Adjusting for the timing of vaccination in
185 the current season did not notably change the marked repeat vaccination effect for A/H3N2 and had
186 little to no effect for A/H1N1pdm09 and type B (Figure 1B; SFig 3.3 shows variation in estimates by
187 season and site; SFig 3.5 shows results did not vary significantly by age group).

188 In models accounting for the timing of vaccination and previous season vaccination, we observed
189 that odds of infection against all three (sub)types increased with time since current season
190 vaccination (Figure 1C). Compared with individuals not vaccinated in either season (who had the
191 highest risk of testing positive), current-season vaccinees who vaccinated 2-9 weeks before testing
192 had lower OR (0.29 [95%CI:0.23-0.35]) for A/H1N1pdm09-associated illness than those vaccinated
193 18-21 weeks before testing (OR=0.66; 95%CI:0.56-0.78). In the 2014-2015 season, when there was
194 a mismatch between the A/H3N2 component and the circulating strains, the odds of infection
195 decreased with time from vaccination in Wisconsin (SFig 3.1).

196 4.2 Impact of clinical infection history

197 Prior clinical infections of the homologous (sub)type protected against clinical infections of type B or
198 A/H3N2, with more recent infections conferring stronger protection (Figure 2A); those infected with
199 type B more than 6 seasons ago had 3.60 (95%CI:1.08-11.9) times the odds of testing positive for
200 type B in the current season than those who were clinically infected in the previous 1-2 seasons
201 (Figure 2A). A similar trend emerged for clinical infections against A/H3N2 (OR=32.4, 95%CI:4.4-242,
202 Figure 2A). We did not find clinical infections of a heterologous (sub)type to be protective (SFig 4.1).
203 Due to the limited number of A/H1N1pdm09 infections during our enrollment period, we could not
204 assess the impact of homologous infection with A/H1N1pdm09.

205 We found that having a confirmed influenza virus infection in the previous season appeared to
206 influence the decision to vaccinate in the current season. Individuals unvaccinated in the previous
207 season were more likely to vaccinate in the current season (OR=1.30, 95%CI:1.18-1.44) if they were

208 clinically infected in the previous season than if they were not infected. However, individuals who
209 became infected after being vaccinated in the previous season were as likely to be unvaccinated in
210 the current season as those not infected (OR=0.96, 95%CI:0.85-1.10), with the exception of the
211 oldest age group, which tended to vaccinate again (Figure 2B).

212 Adjusting for confounding by clinical infection in the previous season had little influence on the
213 estimated effect of repeated vaccination (Figure 2C). After adjustment, repeat vaccinees enrolled
214 during the 2008-2009 season and between the 2010-2011 and the 2018-2019 seasons had 1.29
215 (95%CI:0.96-1.71) times the odds of testing positive for A/H1N1dpm09 than those who were only
216 vaccinated in the current season. Accounting for clinical infection history did not significantly change
217 the estimated effect of repeated vaccination against A/H3N2 (from 1.02, 95%CI:0.84-1.23 to 1.06,
218 95%CI:0.87-1.31 post adjustment) or type B (from 1.18, 95%CI:0.91-1.53 to 1.17, 95%CI:0.92-1.52
219 post adjustment). Excluding the 194 individuals who presented with acute respiratory illness but
220 refused enrollment in the previous season did not significantly change the results (SFig 4.2). Not
221 adjusting for waning vaccine protection in the weighted outcome model yielded similar results (SFig
222 4.3, Supplemental Section 4).

223

224 4.3 Impact of clinical and subclinical infection history

225 4.3.1 Infection block hypothesis

226 In the previous section we estimated that repeat vaccinees had a 10% increase (OR~1.1) in the odds
227 of current-season infection, an effect that could be partially mediated by clinical infection in the prior
228 season, a version of the infection block hypothesis. In this section, we use a theoretical model to
229 explore the degree to which subclinical infection – which would not be observed in any of the data
230 sets we consider – could fully explain the observed repeat vaccination effect.

231 To produce the estimated effect of repeated vaccination (i.e., OR for clinical infection comparing
232 repeat with non-repeat vaccinees against A/H3N2 or type B of 1.1) in the US Flu VE Network, non-
233 repeat vaccinees would have to be subclinically infected in the prior season at a substantially higher
234 rate than repeat vaccinees (Figure 3; SFig 5.1). For example, if subclinical infection reduces the

235 probability of next-season clinical infection by 70% (dark green curve in Figure 3A), ~5% of repeat
236 vaccinees and ~15% of non-repeat vaccinees would have to have been subclinically infected in the
237 prior season to observe the estimated effect.

238 For thoroughness, we showed that prior-season clinical infection is unlikely to be an important
239 mediator in this relationship between prior-season vaccination and the odds of current-season clinical
240 infection (Supplemental Section 6; SFig 6.1).

241 Compared with estimates from a low-clinical-incidence setting, in a high-incidence setting, we
242 expect a greater excess of clinical infections in the current season among repeat vaccinees
243 compared with non-repeat vaccinees (SFig 5.2).

244 4.3.2 Enhanced vaccine immunogenicity hypothesis

245 If recent infection improves vaccine immunogenicity and thus vaccine-induced protection, a smaller
246 difference in rates of subclinical infection between repeat and non-repeat vaccinees would generate
247 the same estimated effect of repeated vaccination against infection in the current season (SFig 5.3).
248 For example, in the scenario described in the second paragraph of section 4.3.1, we would observe
249 the expected effect of repeated vaccination (OR=1.1) when the difference in the rate of subclinical
250 infection between repeat and non-repeat vaccinees is 10% (e.g., ~5% and ~15% respectively),
251 assuming subclinical infection reduces the probability of future clinical infection by 70%. But if recent
252 infection boosts VE from 50% to 76%, a smaller difference in subclinical attack rates (~5% in repeat
253 vaccinees and ~12% in non-repeat vaccinees) and weaker protection from subclinical infection (from
254 70% to 30%) can produce the same estimated effect.

255

256 5 Discussion

257 Observational studies[7–13,15,16], mostly using the test-negative design[8–13,15,16], have provided
258 critical information on influenza VE. These studies can have biases and uncontrolled confounding
259 that affect inference, including inference of VE in different subpopulations[33,39–42]. Reduced VE in
260 repeat vaccinees has been a troubling, intermittent, and largely unexplained phenomenon[8,9]. We

261 studied a component phenomenon, which is that the absolute risk (or odds) of infection among
262 vaccinees in the current season is less if they were unvaccinated last season than if they were
263 vaccinated last season. We observed waning of vaccine protection and repeat vaccinees' tendency
264 to vaccinate earlier within a season compared with non-repeat vaccinees. We showed that clinical
265 infection impacts individuals' decisions to vaccinate in the next season, and clinical infections in the
266 past 1-2 seasons strongly protect against reinfection. However, these potentially biasing factors –
267 prior-season infection and timing of vaccination – could not fully explain the higher risk of infection in
268 the repeat vaccinees vs. non-repeat vaccinees in our study population. We showed that the residual
269 repeat vaccination effect might be explained by different rates of subclinical infection between repeat
270 and non-repeat vaccinees via two proposed mechanisms, the infection block hypothesis[4,24-26] and
271 enhanced vaccine immunogenicity and protection post-infection[28,43]. The difference in rates of
272 subclinical infection between the two groups and its variation from one season to the next might thus
273 underlie variability in estimated effects of repeated vaccination.

274 Mostly due to lack of data, clinical infection history has typically not been accounted for when
275 estimating influenza VE. We found that accounting for clinical infection history did not substantially
276 change the estimated effect of repeat vaccination, indicating that confounding by prior-season clinical
277 infection may not fully explain the elevated odds of infection among repeat vaccinees. Aside from its
278 potential role as a confounder, we found clinical infection unlikely to act as an important mediator.
279 Verifying the finding in surveillance data requires methods that can tease apart the direct and indirect
280 effect of vaccination after taking into account the interaction of vaccination and infection over a multi-
281 year period.

282 The sensitivity of the estimated effect of repeated vaccination to differences in subclinical attack
283 rates and infection-associated protection suggests a possible explanation for the observed variability
284 in the estimated effect of repeat vaccination and other VE measures across locations and time. There
285 is well-known spatiotemporal variation in the sizes of influenza epidemics and in circulating clades
286 that could affect the amount of protection conferred by infection in different populations. Our results
287 suggest a need to try to account more precisely for past infections, so that VE estimates can be
288 compared across populations stratified by similar infection history. Longitudinal cohort studies that
289 involve blood collection, active surveillance, and sequencing can be useful for identifying subclinical

290 infections, and coupling these observations with healthcare-seeking behavior and PCR testing can
291 help test the infection block and enhanced immunogenicity hypotheses[44]. Eventually, stratification
292 on infection history may be possible through surrogate immune markers.

293 The study has several limitations. Throughout our analysis, we assumed that influenza
294 vaccination with any type of influenza vaccine confers complete protection in a subset of vaccinees.
295 We did not consider “leaky” vaccine effects, where vaccines are partially protective in all recipients,
296 and which can lead to an observed decline in VE estimates even when vaccine protection does not
297 wane [45]. Although the test-negative study, by selecting only patients who seek medical care, is
298 designed to reduce the difference in health-seeking behavior between cases and non-cases, it does
299 not eliminate it[40]. We did not explore birth cohort effects or the effects of antigenic distance on
300 protection[46–49]. Since we assumed individuals without an enrollment record in the previous season
301 were not clinically infected, some of them may have been misclassified.

302 The practical benefits of annual vaccination programs should not be extrapolated from this
303 analysis of the relative risk of infection in repeat vaccinees compared to non-repeat vaccinees. The
304 choice between an annual and a non-annual vaccination program should be based on assessments
305 of the infection risk among all repeat and non-repeat vaccinees as well as the unvaccinated. Our
306 analysis does not compare the risk of infection between repeat vaccinees and those vaccinated in the
307 prior season only, who would be part of a hypothetical non-annual vaccination program.

308 Our study provides evidence that two potential factors, timing of vaccination and clinical infection
309 history, cannot fully explain the increased infection risk in repeat vaccinees compared with non-
310 repeat vaccinees. Clinical infection history is further unlikely to act as a strong mediator to explain the
311 repeated vaccination effect. Instead, under reasonable assumptions, the infection block and
312 enhanced-immunogenicity hypotheses involving subclinical infection in the previous season may
313 explain the effect, thus acting as a potential mediator. Estimation of VE requires careful consideration
314 of both time since vaccination and infection history of different subpopulations.

315

316 **Acknowledgements**

317 QB, BAD, ML, SC conceived of the study. HQM, ETM, MG, KJW, BG, BF collected the data. QB
318 performed the analyses and generated all figures. QB, BAD, ML, SC wrote the manuscript. All
319 authors revised the manuscript. We thank Benjamin A. Cowling for comments. Authors report no
320 conflict of interest.

321

322 Investigators and collaborators in the US Flu VE Network Investigators include:

323 Baylor Scott & White Health – Kempapura Murthy, Chandni Raiyani, Kayan Dunnigan, Muffadal
324 Mamawala

325 CDC – Jessie R. Chung, Manish Patel

326 Henry Ford Medical Center – Lois Lamerato

327 Kaiser Permanente Washington – Michael L. Jackson, C. Hallie Phillips, Erika Kiniry

328 Marshfield Clinic Research Institute – Edward A. Belongia, Jennifer P. King

329 University of Michigan – Arnold S. Monto

330 University of Pittsburgh – Richard K. Zimmerman, Mary Patricia Nowalk, Krissy Moehling Geffel

331

332 References

333 1. Vaccines against influenza WHO position paper – November 2012. *Wkly Epidemiol Rec.* **2012**;
334 87(47):461–476.

335 2. Principi N, Camilloni B, Esposito S, ESCMID Vaccine Study Group (EVASG). Influenza
336 immunization policies: Which could be the main reasons for differences among countries? *Hum*
337 *Vaccin Immunother.* **2018**; 14(3):684–692.

338 3. Hoskins TW, Davies J, Smith AJ, Allchin A, Miller C, Pollock TM. INFLUENZA AT CHRIST'S

- 339 HOSPITAL: MARCH, 1974 [Internet]. *The Lancet*. 1976. p. 105–108. Available from:
340 [http://dx.doi.org/10.1016/s0140-6736\(76\)93151-2](http://dx.doi.org/10.1016/s0140-6736(76)93151-2)
- 341 4. Hoskins TW, Davies JR, Smith AJ, Miller CL, Allchin A. Assessment of inactivated influenza-A
342 vaccine after three outbreaks of influenza A at Christ’s Hospital. *Lancet*. **1979**; 1(8106):33–35.
- 343 5. Skowronski DM, Janjua NZ, De Serres G, et al. A Sentinel Platform to Evaluate Influenza
344 Vaccine Effectiveness and New Variant Circulation, Canada 2010–2011 Season [Internet].
345 *Clinical Infectious Diseases*. 2012. p. 332–342. Available from:
346 <http://dx.doi.org/10.1093/cid/cis431>
- 347 6. Ng S, Fang VJ, Ip DKM, et al. Humoral antibody response after receipt of inactivated seasonal
348 influenza vaccinations one year apart in children. *Pediatr Infect Dis J*. **2012**; 31(9):964–969.
- 349 7. Ohmit SE, Petrie JG, Malosh RE, et al. Influenza Vaccine Effectiveness in the Community and
350 the Household [Internet]. *Clinical Infectious Diseases*. 2013. p. 1363–1369. Available from:
351 <http://dx.doi.org/10.1093/cid/cit060>
- 352 8. Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G.
353 Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. *Expert*
354 *Rev Vaccines*. **2017**; 16(7):1–14.
- 355 9. Ramsay LC, Buchan SA, Stirling RG, et al. The impact of repeated vaccination on influenza
356 vaccine effectiveness: a systematic review and meta-analysis. *BMC Med*. **2019**; 17(1):9.
- 357 10. McLean HQ, Thompson MG, Sundaram ME, et al. Impact of Repeated Vaccination on Vaccine
358 Effectiveness Against Influenza A(H3N2) and B During 8 Seasons [Internet]. *Clinical Infectious*
359 *Diseases*. 2014. p. 1375–1385. Available from: <http://dx.doi.org/10.1093/cid/ciu680>
- 360 11. Ohmit SE, Thompson MG, Petrie JG, et al. Influenza Vaccine Effectiveness in the 2011–2012
361 Season: Protection Against Each Circulating Virus and the Effect of Prior Vaccination on
362 Estimates [Internet]. *Clinical Infectious Diseases*. 2014. p. 319–327. Available from:
363 <http://dx.doi.org/10.1093/cid/cit736>
- 364 12. Skowronski DM, Chambers C, Sabaiduc S, et al. A Perfect Storm: Impact of Genomic Variation


- 365 and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season.
366 Clin Infect Dis. **2016**; 63(1):21–32.
- 367 13. Valenciano M, Kissling E, Reuss A, et al. Vaccine effectiveness in preventing laboratory-
368 confirmed influenza in primary care patients in a season of co-circulation of influenza
369 A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe
370 2014/15. Euro Surveill. **2016**; 21(7):ii=30139.
- 371 14. Kissling E, Pozo F, Buda S, et al. Low 2018/19 vaccine effectiveness against influenza A(H3N2)
372 among 15-64-year-olds in Europe: exploration by birth cohort. Euro Surveill [Internet]. **2019**;
373 24(48). Available from: <http://dx.doi.org/10.2807/1560-7917.ES.2019.24.48.1900604>
- 374 15. McLean HQ, Thompson MG, Sundaram ME, et al. Influenza vaccine effectiveness in the United
375 States during 2012-2013: variable protection by age and virus type. J Infect Dis. **2015**;
376 211(10):1529–1540.
- 377 16. Kissling E, Pozo F, Buda S, et al. Low 2018/19 vaccine effectiveness against influenza A(H3N2)
378 among 15–64-year-olds in Europe: exploration by birth cohort [Internet]. Eurosurveillance. 2019.
379 Available from: <http://dx.doi.org/10.2807/1560-7917.es.2019.24.48.1900604>
- 380 17. Ferdinands JM, Shay DK. Magnitude of potential biases in a simulated case-control study of the
381 effectiveness of influenza vaccination. Clin Infect Dis. **2012**; 54(1):25–32.
- 382 18. Ray GT, Lewis N, Klein NP, et al. Intraseason Waning of Influenza Vaccine Effectiveness. Clin
383 Infect Dis. **2019**; 68(10):1623–1630.
- 384 19. Ferdinands JM, Gaglani M, Martin ET, et al. Waning Vaccine Effectiveness Against Influenza-
385 Associated Hospitalizations Among Adults, 2015–2016 to 2018–2019, United States Hospitalized
386 Adult Influenza Vaccine Effectiveness Network [Internet]. Clinical Infectious Diseases. 2021. p.
387 726–729. Available from: <http://dx.doi.org/10.1093/cid/ciab045>
- 388 20. Young B, Sadarangani S, Jiang L, Wilder-Smith A, Chen MI-C. Duration of Influenza Vaccine
389 Effectiveness: A Systematic Review, Meta-analysis, and Meta-regression of Test-Negative
390 Design Case-Control Studies. J Infect Dis. **2018**; 217(5):731–741.

- 391 21. Jiménez-Jorge S, Mateo S de, Delgado-Sanz C, et al. Effectiveness of influenza vaccine against
392 laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population
393 targeted for vaccination. *BMC Infect Dis.* **2013**; 13:441.
- 394 22. Ferdinands JM, Fry AM, Reynolds S, et al. Intraseason waning of influenza vaccine protection:
395 Evidence from the US Influenza Vaccine Effectiveness Network, 2011-12 through 2014-15. *Clin*
396 *Infect Dis.* **2017**; 64(5):544–550.
- 397 23. Fox SJ, Miller JC, Meyers LA (2017) Seasonality in risk of pandemic influenza emergence. *PLoS*
398 *Comput Biol* 13(10): e1005749.
- 399 24. Skowronski DM, Janjua NZ, Hottes TS, De Serres G. Mechanism for Seasonal Vaccine Effect on
400 Pandemic H1N1 Risk Remains Uncertain. *Clin. Infect. Dis.* 2011. p. 831–2; author reply 832–3.
- 401 25. Skowronski DM, De Serres G, Crowcroft NS, et al. Association between the 2008-09 seasonal
402 influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational
403 studies from Canada. *PLoS Med.* **2010**; 7(4):e1000258.
- 404 26. Cowling BJ, Ng S, Ma ESK, et al. Protective Efficacy of Seasonal Influenza Vaccination against
405 Seasonal and Pandemic Influenza Virus Infection during 2009 in Hong Kong [Internet]. *Clinical*
406 *Infectious Diseases.* 2010. p. 1370–1379. Available from: <http://dx.doi.org/10.1086/657311>
- 407 27. Ranjeva, S., Subramanian, R., Fang, V.J. et al. Age-specific differences in the dynamics of
408 protective immunity to influenza. *Nat Commun* 10, 1660 (2019). [https://doi.org/10.1038/s41467-](https://doi.org/10.1038/s41467-019-09652-6)
409 [019-09652-6](https://doi.org/10.1038/s41467-019-09652-6)
- 410 28. Auladell M, Phuong HVM, Mai LTQ, et al. Influenza virus infection history shapes antibody
411 responses to influenza vaccination. *Nat Med.* **2022**; 28(2):363–372.
- 412 29. Krammer F. The human antibody response to influenza A virus infection and vaccination. *Nat*
413 *Rev Immunol.* **2019**; 19(6):383–397.
- 414 30. Hall V, Foulkes S, Insalata F, et al. Protection against SARS-CoV-2 after Covid-19 Vaccination
415 and Previous Infection. *N Engl J Med.* **2022**; 386(13):1207–1220.

- 416 31. VanderWeele TJ. Explanation in causal inference: developments in mediation and interaction
417 [Internet]. *International Journal of Epidemiology*. 2016. p. dyw277. Available from:
418 <http://dx.doi.org/10.1093/ije/dyw277>
- 419 32. Hernan MA, Robins JM. *Causal Inference*. CRC Press; 2019.
- 420 33. Gaglani M, Pruszynski J, Murthy K, et al. Influenza Vaccine Effectiveness Against 2009
421 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013–2014 in the United
422 States [Internet]. *Journal of Infectious Diseases*. 2016. p. 1546–1556. Available from:
423 <http://dx.doi.org/10.1093/infdis/jiv577>
- 424 34. Zimmerman RK, Nowalk MP, Chung J, et al. 2014-2015 Influenza Vaccine Effectiveness
425 in the United States by Vaccine Type. *Clin Infect Dis*. 2016 Dec 15;63(12):1564-1573.
426 <https://doi.org/10.1093/cid/ciw635>.
- 427 35. Jackson ML, Chung JR, Jackson LA, et al. Influenza Vaccine Effectiveness in the United States
428 during the 2015-2016 Season. *N Engl J Med*. 2017 Aug 10;377(6):534-543.
429 <https://doi.org/10.1056/NEJMoa1700153>.
- 430 36. Kieke AL, Kieke BA Jr, Kopitzke SL, et al. Validation of Health Event Capture in the Marshfield
431 Epidemiologic Study Area. *Clin Med Res*. **2015**; 13(3-4):103–111.
- 432 37. Cohen C, Kleynhans J, Moyes J, et al. Asymptomatic transmission and high community burden
433 of seasonal influenza in an urban and a rural community in South Africa, 2017–18 (PHIRST): a
434 population cohort study. *The Lancet Global Health*. 2021; 9:e863–e874.
- 435 38. Jackson ML, Jackson LA, Kieke B, et al. Incidence of medically attended influenza infection and
436 cases averted by vaccination, 2011/2012 and 2012/2013 influenza seasons [Internet]. *Vaccine*.
437 2015. p. 5181–5187. Available from: <http://dx.doi.org/10.1016/j.vaccine.2015.07.098>
- 438 39. Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding
439 and bias in observational studies. *Epidemiology*. **2010**; 21(3):383–388.
- 440 40. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical Basis of the Test-Negative Study

- 441 Design for Assessment of Influenza Vaccine Effectiveness. *Am J Epidemiol.* **2016**; 184(5):345–
442 353.
- 443 41. Chua H, Feng S, Lewnard JA, et al. The Use of Test-negative Controls to Monitor Vaccine
444 Effectiveness: A Systematic Review of Methodology. *Epidemiology.* **2020**; 31(1):43–64.
- 445 42. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness
446 [Internet]. *Vaccine.* 2013. p. 2165–2168. Available from:
447 <http://dx.doi.org/10.1016/j.vaccine.2013.02.053>
- 448 43. Altarawneh HN, Chemaitelly H, Ayoub HH, et al. Effects of Previous Infection and
449 Vaccination on Symptomatic Omicron Infections. *N Engl J Med.* **2022**; 387(1):21–34.
- 450 44. Monto AS, DeJonge PM, Callear AP, et al. Coronavirus Occurrence and Transmission Over 8
451 Years in the HIVE Cohort of Households in Michigan. *J Infect Dis.* **2020**; 222(1):9–16.
- 452 45. Tokars JI, Patel MM, Foppa IM, Reed C, Fry AM, Ferdinands JM. Waning of Measured Influenza
453 Vaccine Effectiveness Over Time: The Potential Contribution of Leaky Vaccine Effect. *Clin Infect*
454 *Dis.* **2020**; 71(10):e633–e641.
- 455 46. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual influenza
456 vaccination. *Proc Natl Acad Sci U S A.* **1999**; 96(24):14001–14006.
- 457 47. Arevalo P, McLean HQ, Belongia EA, Cobey S. Earliest infections predict the age distribution of
458 seasonal influenza A cases. *Elife* [Internet]. **2020**; 9. Available from:
459 <http://dx.doi.org/10.7554/eLife.50060>
- 460 48. Skowronski DM, Chambers C, De Serres G, et al. Serial Vaccination and the Antigenic Distance
461 Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2) Epidemics in Canada,
462 2010-2011 to 2014-2015. *J Infect Dis.* **2017**; 215(7):1059–1099.
- 463 49. Flannery B, Smith C, Garten RJ, et al. Influence of Birth Cohort on Effectiveness of 2015-2016
464 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1)
465 Virus in the United States. *J Infect Dis.* **2018**; 218(2):189–196.

466



467

468 **Figure 1: That repeat vaccinees vaccinate earlier in a season, which increases their**
 469 **susceptibility to infection due to waning vaccine protection, does not explain their**
 470 **odds of infection compared to non-repeat vaccinees.** A) Average calendar week of vaccination
 471 among repeat and non-repeat vaccinees over the study enrollment seasons. Repeat vaccinees
 472 consistently get vaccinated earlier than non-repeat vaccinees. B) Adjusted odds ratio for clinical
 473 infection among individuals vaccinated this season stratified based on whether the individuals were
 474 also vaccinated in the prior season (repeat vaccinees) or not (non-repeat vaccinees) before (yellow)
 475 and after (red) adjusting for the timing of vaccination within a season. Site- and season- specific data

476 are shown in SFig 3.3). C) Adjusted odds ratio of clinical infection comparing individuals vaccinated
477 2-9, 10-13, 14-17, 18-21, and 22+ weeks in the current season (but not in the previous season)
478 before testing positive with respect to those not vaccinated in either season. Site- and season-
479 specific data are shown in SFig 3.1 and age specific data are shown in SFig 3.5. See Supplemental
480 Section 3 for detailed definitions of the quantities reported here.




Figure 2: Recent clinical infections, which induce non-vaccinees to vaccinate the next season and which can protect against clinical reinfection for years, cannot explain the effect of repeated vaccination. A) Association between recent clinical infections and odds of current-influenza-season clinical infection. More distant clinical infections of the homologous subtype are associated with a higher odds of current-season clinical infection. B) Tendency to switch vaccination status in the current influenza season after clinical infection in the previous season. Compared with individuals without confirmed infections, unvaccinated individuals who were clinically infected in the

previous season were more likely to vaccinate in the current season. C) Estimated effect of repeat vaccination after adjusting for recent clinical infections. Adjusted odds ratio for clinical infection comparing repeat vaccinees with non-repeat vaccinees before (light blue) and after adjusting for clinical infection status in the previous season (dark blue) using inverse-probability weighting. Results stratified by age group are shown in SFig 4.4. They suggest a marginally significantly higher adjusted odds of infection in repeat vaccinees >19 years old for H1N1. Adjustment did not significantly impact the estimates. In all panels, error bars indicate 95% confidence intervals.




Figure 3: Subclinical infection might be able to explain the effect of repeated vaccination, aligning with the hypotheses of infection block (A) and enhanced immunogenicity (B). A) The fraction of repeat and non-repeat vaccinees who would need to have been subclinically infected in the previous season to reproduce the estimated effect of repeated vaccination in the US Flu VE Network (i.e., $OR=1.1$), given various assumptions of predetermined protection against clinical infection after subclinical infection (i.e., 30%, 50%, 70%). See Supplemental Section 5 for detailed methods. Under this hypothesis, subclinical infection is more common among those unvaccinated in the previous season (green lines above the 45-degree line) and reduces risk of infection this season. Only the plausible range of subclinical attack rate among repeat vaccinees (x-axis) and non-repeat vaccinees (y-axis; 0-50%) are shown in the figure. B) The absolute increase in VE (shown in the legend) from a baseline VE of 50% needed to reproduce the estimated effect of repeated

vaccination in the US Flu VE Network (OR=1.1). Under this hypothesis, vaccination this season is more effective in those infected subclinically in the previous season, who are (as in A) more common among those unvaccinated in the previous season. The figure shows the scenario where the effectiveness of subclinical infection against future clinical infection is 30%. The uncolored portion of the figure represents the population where a boost in VE after infection will not generate the estimated effect of repeated vaccination (OR of 1.1). The results in both panels assume that vaccine effectiveness against clinical infection is 50%; clinical attack rate among vaccinees in a season is 1%; current-season clinical attack rate among the subset of current-season vaccinees not infected in the previous season is 1.5%; and clinical infection in the previous season perfectly protects against clinical infection in the following season.